A biopharmaceutical startup led by the former CEO of one Jacksonville's fastest-growing companies debuted on the Nasdaq stock exchange on Friday, priced at $5 a share.
The drug being developed by Cadrenal is an oral anti-coagulant that Pham has previously said could replace warfarin as a standard medication. The company is looking to sell 1.4 million shares of stock, raising $7 million before expenses. Various existing shareholders, including the Boys & Girls Club of Northeast Florida, are expected to sell another 1.7 million shares.
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: JaxBizJournal - 🏆 599. / 51 Read more »
Source: KRLD - 🏆 75. / 68 Read more »
Source: JaxBizJournal - 🏆 599. / 51 Read more »